Get the Stockscreener App
1.50
2.74%
0.04
After Hours:
1.51
0.01
+0.67%
Inmune Bio Inc stock is traded at $1.50, with a volume of 434.90K.
It is up +2.74% in the last 24 hours and down -18.92% over the past month.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.
See More
Previous Close:
$1.46
Open:
$1.43
24h Volume:
434.90K
Relative Volume:
0.82
Market Cap:
$38.81M
Revenue:
$155.00K
Net Income/Loss:
$-30.01M
P/E Ratio:
-0.8982
EPS:
-1.67
Net Cash Flow:
$-11.98M
1W Performance:
-0.66%
1M Performance:
-18.92%
6M Performance:
-80.92%
1Y Performance:
-69.20%
1-Day Range:
$1.43
$1.51
1-Week Range:
$1.38
$1.5605
52-Week Range:
$1.38
$11.64
Inmune Bio Inc Stock (INMB) Company Profile
Name
Inmune Bio Inc
Sector
Industry
Phone
(858) 964-3720
Address
225 NE MIZNER BLVD, SUITE 640, BOCA RATON, CA
Compare INMB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INMB
Inmune Bio Inc
|
1.50 | 38.81M | 155.00K | -30.01M | -11.98M | -1.67 |
|
ARGX
Argen X Se Adr
|
918.53 | 57.24B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.52 | 110.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
201.62 | 42.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
363.92 | 41.68B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
725.34 | 74.02B | 14.25B | 4.58B | 3.88B | 41.77 |
Inmune Bio Inc Stock (INMB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-01-25 | Downgrade | BTIG Research | Buy → Neutral |
| Jul-01-25 | Downgrade | Scotiabank | Sector Outperform → Sector Underperform |
| Jan-28-25 | Initiated | Rodman & Renshaw | Buy |
| Oct-21-24 | Initiated | Alliance Global Partners | Buy |
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-22-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-01-23 | Initiated | Robert W. Baird | Outperform |
| May-24-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
| Apr-21-21 | Initiated | B. Riley Securities | Buy |
| Jan-22-21 | Reiterated | Maxim Group | Buy |
| Sep-01-20 | Initiated | BTIG Research | Buy |
| Jul-15-20 | Reiterated | H.C. Wainwright | Buy |
View All
Inmune Bio Inc Stock (INMB) Latest News
Does INmune Bio Inc. stock trade at a discount to peersMarket Trend Summary & Reliable Volume Spike Trade Alerts - newser.com
Why INmune Bio Inc. stock is a value investor pick2025 Market Trends & Long Hold Capital Preservation Plans - newser.com
Is INmune Bio Inc. stock positioned for long term growthWeekly Stock Analysis & Free Safe Capital Growth Stock Tips - newser.com
INmune Bio Approves Option Repricing Proposal - TipRanks
INmune Bio, Inc. Announces Presentations at 18th Clinical Trials on Alzheimer’s Disease Conference - Quiver Quantitative
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference - Bluefield Daily Telegraph
INmune Bio (INMB) plans XPro1595 Phase 2 Alzheimer’s and EMACC talks at 18th CTAD - Stock Titan
How INmune Bio Inc. stock reacts to Fed rate cutsJuly 2025 Technicals & Expert Curated Trade Setup Alerts - newser.com
Analyzing recovery setups for INmune Bio Inc. investorsDollar Strength & Low Risk Investment Opportunities - newser.com
Statistical indicators supporting INmune Bio Inc.’s strengthShare Buyback & AI Powered Market Trend Analysis - newser.com
How INmune Bio Inc. stock benefits from global expansionPortfolio Value Summary & Accurate Intraday Trade Tips - newser.com
Will INmune Bio Inc. stock outperform tech sector in 2025Weekly Profit Report & Proven Capital Preservation Methods - newser.com
Is INmune Bio Inc. a candidate for recovery play2025 Support & Resistance & Safe Entry Trade Signal Reports - newser.com
Heatmap analysis for INmune Bio Inc. and competitors2025 Market Outlook & Fast Entry and Exit Trade Plans - newser.com
Sentiment analysis tools applied to INmune Bio Inc.Dollar Strength & Free Real-Time Market Sentiment Alerts - newser.com
Is it time to cut losses on INmune Bio Inc.2025 Earnings Impact & Step-by-Step Trade Execution Guides - newser.com
Short interest data insights for INmune Bio Inc.2025 Technical Overview & Free Weekly Watchlist of Top Performers - newser.com
Inmune Bio Advances Immunotherapy Pipeline with Phase 2 Completion - MSN
What makes INmune Bio Inc. stock attractive to growth fundsJuly 2025 Update & AI Forecasted Entry/Exit Points - newser.com
Candlestick signals on INmune Bio Inc. stock today2025 Dividend Review & Community Supported Trade Ideas - newser.com
Inmune Bio, Inc. Announces Key Developments in Clinical Programs - TradingView
Is INmune Bio Inc. stock overvalued by current metricsPortfolio Value Summary & Daily Volume Surge Signals - newser.com
Sector ETF performance correlation with INmune Bio Inc.Trade Ideas & AI Enhanced Trading Signals - newser.com
Inmune Bio Inc Stock (INMB) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.08%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):